Northwest Biotherapeutics, Inc. (NWBO)

Market Cap	434.00M +7.5%
Revenue (ttm)	1.38M -0.3%
Net Income	-61.48M
EPS	-0.04
Shares Out	1.64B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	762,610
Average Volume	4,671,585
Open	0.2647
Previous Close	0.2639
Day's Range	0.2501 - 0.2800
52-Week Range	0.1900 - 0.3680
Beta	-0.74
RSI	70.38
Earnings Date	May 20, 2026

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 105
• Stock Exchange: OTCMKTS
• Ticker Symbol: NWBO

Financial Performance

In 2025, Northwest Biotherapeutics's revenue was $1.38 million, a decrease of -0.29% compared to the previous year's $1.38 million. Losses were -$61.48 million, -27.84% less than in 2024.